Persistence of clinically significant portal hypertension after eradication of HCV in patients with advanced cirrhosis.

: This prospective study of 34 patients with HCV-cirrhosis (17 HIV+) with baseline clinically significant portal hypertension (CSPH; HVPG ≥ 10 mmHg) and SVR after DAAs therapy, showed that disappearance of CSPH (primary endpoint) is a rare event (6/18 patients; 18 %), indicating a persistent risk of clinical progression or death.